Pipeline Overview

Cingulate Therapeutics currently has two (2) products, CTX-1301 and CTX-1302, in clinical development that have the potential to capture $1.5 – 2 billion of the U.S. ADHD market annually. Both therapies utilize an innovative, flexible core tableting technology designed to fulfill long-standing unmet needs of patients suffering with ADHD. No known competitive product currently in development is poised to overcome all unmet needs.

  • No available ADHD treatment
    • works fast (less than 30 minutes)
    • lasts the entire active day (14-16 hours)
    • minimizes the “afternoon crash” with a controlled descent of the API
    • and provides excellent tolerability with minimal impact on appetite and sleep